Source: Wall Street
Since October 1st, Merck & Co Inc(Merck & Co. Inc.) released experimental data show that its COVID-19 oral pill molnupiravir can reduce the risk of hospitalization or death of COVID-19 cases by about 50%.The market began to shift its focus to drugs that are easy to take and can combat mild COVID-19 's symptoms.
A fierce competition in the COVID-19 drug market also kicked off.
Japanese drugmaker Shionogi & Co. Ltd. Said Friday that COVID-19, an oral drug it is developing, could be a $2 billion drug that could be used in conjunction with similar drugs from Merck & Co Inc.
Teshirogi, chief executive of Yamano Pharmaceuticals, was quoted by Bloomberg as saying that the company expected to obtain late-stage trial data on the drug by December and would quickly apply to Japanese regulators for approval. He said the company will start producing the drug this month and expects to produce 1 million doses by the beginning of next year and 6 million to 7 million doses in the next fiscal year ending March 2023.
Teshirogi says:
If the United States, Europe and Japan can all adopt Merck & Co Inc's price of $700, I think (our company COVID-19 oral medicine) can achieve at least $10-2 billion in sales in the first few years.
Salt Yeyi's drug is a protease inhibitor, which, unlike Merck & Co Inc's drug, targets different regions in the process of virus replication. Because of this, Teshirogi says, they are likely to be used together-a possibility that the two companies are discussing. But he said regulatory approval is needed before the two compounds can be tested together.
In addition to the wild righteousness of salt, Pfizer IncPharmaceutical giants such as Pfizer Inc.) and Roche Holding AG are also developing drug candidates for COVID-19.Analysts estimate that annual sales of successful drugs could be as high as $10 billion.
Teshirogi representsIn the short term, the global demand for COVID-19 's oral medicine will be very strong, and production capacity will be a challenge for most drugmakers.The company is in negotiations with "6-7" global pharmaceutical companies to jointly develop COVID-19 oral tablets for global clinical trials, production and distribution.
Merck & Co Inc has signed a $1.2 billion agreement with the US government and is negotiating with several countries to supply it with the drug.
Risk reminder and exemption clause
There are risks in the market, so investment should be cautious. This article does not constitute personal investment advice, nor does it take into account the special investment objectives, financial situation or needs of individual users. Users should consider whether any comments, opinions or conclusions in this article are in line with their specific circumstances. If you invest accordingly, you will bear your own responsibility.